All In Biotech

Drug Trial Radar · NCT00460525

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali

Last checked: Nov 20, 2026Latest source record: Nov 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

May 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Sponsor type
Federal agency
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Walter Reed Army Institute of Research (WRAIR); GlaxoSmithKline; University of Maryland
First posted
Apr 16, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 1 year, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria vaccine (FMP2.1/AS02A) to the number of children who get malaria after receiving a vaccine for rabies (an approved vaccine that does not prevent malaria). The children will be assigned to one of the vaccine groups by chance. Participants and doctors will not know which vaccine was given. Study participants will include 400 children, ages 1-6 years, living in Bandiagara, Mali. Children will receive 3 vaccine doses, by injection, to their upper arm. Study procedures will include physical exams and several blood samples. Participants will be involved in the study for 26 months.

Conditions

  • Plasmodium Falciparum Malaria

Interventions

  • FMP2.1/AS02ABiological

    3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).

  • Rabies VaccineBiological

    White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First VaccinationTime frame: 0-7 days after first vaccination
  2. Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.Time frame: 0-7 days after the second vaccination
  3. Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.Time frame: 0-7 days after the third vaccination
  4. Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First VaccinationTime frame: Day 0-29 after first vaccination
  5. Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second VaccinationTime frame: Day 0-29 after second vaccination
  6. Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third VaccinationTime frame: Day 0-29 after third vaccination
  7. Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.Time frame: Occurring between randomization and 6 months after the assigned date of the 3rd immunization.
  8. Number of Subjects Reporting Serious Adverse EventsTime frame: 24 months after initial vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Bamako, Malaria Research and Training Center

    Bamako, Mali

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.